NCT00269217

Lipid Efficacy Study (0524B-022)(COMPLETED)

A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,400 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

Conditions

• Primary Hypercholesterolemia
• Mixed Hyperlipidemia

Interventions

Type	Name	Description
DRUG	niacin (+) laropiprant (+) simvastatin	Duration of Treatment 12 Weeks
DRUG	Comparator: niacin (+) laropiprant	Duration of Treatment 12 Weeks
DRUG	Comparator: simvastatin	Duration of Treatment 12 Weeks

Timeline

• Start date: 2006-01-01
• Primary completion: 2007-01-01
• Completion: 2007-01-01
• First posted: 2005-12-23
• Last updated: 2017-04-07